Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 1/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.48 |
| ▸ | PDE5A | O76074 | 1/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.47 |
| ▸ | TCF7L2 | Q9NQB0 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | GRK6 | P43250 | 1/20 | 0.44 |
| ▸ | ACP1 | P24666 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3110419 | 0.89 | CCNE1 (0.52) | CCNE2CCNE1CDK2APPPOLB | |
| SCHEMBL12170176 | 0.84 | KCNA5 (0.61) | CCNE2CCNE1CDK2APPPOLB | |
| SCHEMBL1685041 | 0.81 | APP (0.74) | APPPOLBEGFRNR2F2PDE5A | |
| SCHEMBL3108353 | 0.81 | CCNE2 (0.54) | CCNE2CCNE1CDK2APPPOLB | |
| Hydrochloric Acid SCHEMBL1685081 | 0.80 | APP (0.72) | APPPOLBEGFRNR2F2PDE5A | |
| SCHEMBL15619030 | 0.77 | CCNE2 (0.68) | CCNE2CCNE1CDK2APPPOLB | |
| SCHEMBL3112153 | 0.77 | EGFR (0.54) | APPPOLBEGFRNR2F2LMNA | |
| SCHEMBL3108883 | 0.76 | MEN1 (0.60) | CCNE2CCNE1CDK2APPPOLB | |
| SCHEMBL3115949 | 0.76 | HRH4 (0.54) | CCNE2CCNE1CDK2APPPOLB | |
| SCHEMBL3115102 | 0.76 | HTT (0.56) | CCNE2CCNE1CDK2APPPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258145-B2 | Method of treating brain cancer | MYREXIS, INC. (US) | 2012-09-04 | — | — | US | claimed |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | claimed |
| US-7618975-B2 | 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | MYRIAD PHARMACEUTICALS, INC. (US) | 2009-11-17 | — | — | US | claimed |
| US-20080051398-A1 | METHOD OF TREATING BRAIN CANCER | MYRIAD GENETICS, INC. (US) | 2008-02-28 | — | — | US | claimed |
| US-20070249601-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-25 | — | — | US | claimed |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | claimed |
| US-20070244113-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | claimed |
| EP-1833511-A2 | METHOD OF TREATING BRAIN CANCER | MYRIAD GENETICS, INC. (US) | 2007-09-19 | — | — | EP | claimed |
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-09-06 | — | — | US | claimed |
| JP-2007524637-A | — | — | 2007-08-30 | — | — | JP | claimed |
| WO-2006074187-A2 | METHOD OF TREATING BRAIN CANCER | MYRIAD GENETICS, INC. (US) | 2006-07-13 | — | — | WO | claimed |
| EP-1660092-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Myriad Genetics, Inc. (US) | 2006-05-31 | — | — | EP | claimed |
| US-20050137213-A1 | Compounds and therapeutical use thereof | MYRIAD GENETICS, INCORPORATED (US) | 2005-06-23 | — | — | US | claimed |
| WO-2005003100-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | MYRIAD GENETICS, INC. (US) | 2005-01-13 | — | — | WO | claimed |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| EP-1660092-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Myriad Genetics, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050137213-A1 | Compounds and therapeutical use thereof | MYRIAD GENETICS, INCORPORATED (US) | 2005-06-23 | — | — | US | disclosed |
| WO-2005003100-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | MYRIAD GENETICS, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | CCNE2 689/4885CCNE1 542/4885CDK2 119/4885 |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | BAD, CASP3, BAX | CCNE2 901/4885CCNE1 692/4885CDK2 154/4885 |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | CCNE2 542/4885CCNE1 478/4885CDK2 104/4885 |
| US-20070244113-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | CCNE2 689/4885CCNE1 542/4885CDK2 119/4885 |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | CCNE2 689/4885CCNE1 542/4885CDK2 119/4885 |
| US-20050137213-A1 | Compounds and therapeutical use thereof | BAD, CASP3, BAX | CCNE2 689/4885CCNE1 542/4885CDK2 119/4885 |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | CCNE2 689/4885CCNE1 542/4885CDK2 119/4885 |
| US-20070249601-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | CCNE2 689/4885CCNE1 542/4885CDK2 119/4885 |
| US-20080051398-A1 | METHOD OF TREATING BRAIN CANCER | CASP3, CASP7, BAD | CCNE2 1344/4885CCNE1 1081/4885CDK2 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.